{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:42Z","timestamp":1787065842218,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bbmt.2016.03.018","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T00:25:26Z","timestamp":1459556726000},"page":"1197-1205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes"],"prefix":"10.1016","volume":"22","author":[{"given":"Christopher R.","family":"Flowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsiporah B.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar O.","family":"Freytes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Mineishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Braunschweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa F.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulio E.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrance","family":"Comeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Yeager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bence-Bruckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laneuville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.03.018_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428194.2013.806659","article-title":"Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed\/refractory Hodgkin lymphoma","volume":"55","author":"Bains","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.03.018_bib2","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma","volume":"28","author":"Josting","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2016.03.018_bib4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2007.02.006","article-title":"Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation\u2013a similar experience","volume":"13","author":"Santos","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbmt.2008.09.008","article-title":"Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR)","volume":"14","author":"Lazarus","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age","volume":"19","author":"McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bbmt.2009.07.014","article-title":"Busulfan and cyclophosphamide (Bu\/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience","volume":"15","author":"Ulrickson","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3816\/CLML.2010.n.086","article-title":"A\u00a0decade of progress in lymphoma: advances and continuing challenges","volume":"10","author":"Flowers","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2016.03.018_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2009-0162","article-title":"Controversies in the treatment of lymphoma with autologous transplantation","volume":"14","author":"Moskowitz","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2016.03.018_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.03.018_bib11","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","article-title":"The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma","volume":"20","author":"Van Besien","year":"2006","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2016.03.018_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/10428194.2014.921296","article-title":"Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma","volume":"56","author":"Nastoupil","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.03.018_bib14","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.03.018_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.1997.3833197.x","article-title":"BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma","volume":"99","author":"Cortelazzo","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib17","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"Flowers","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bbmt.2016.03.018_bib18","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma","volume":"20","author":"Haioun","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00277-002-0495-y","volume":"81","author":"Glossmann","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","article-title":"BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity","volume":"87","author":"Jo","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib21","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A\u00a0randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.03.018_bib22","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bmt.1703179","article-title":"Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens","volume":"28","author":"Gutierrez-Delgado","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","article-title":"BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.03.018_bib25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbmt.2006.03.016","article-title":"Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen","volume":"12","author":"Aggarwal","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib26","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1097\/MPH.0b013e3181fd6c79","article-title":"High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study","volume":"33","author":"Andion","year":"2011","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2009.07940.x","article-title":"Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide","volume":"148","author":"Dean","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3109\/10428191003611428","article-title":"Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma","volume":"51","author":"Grigg","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.03.018_bib29","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3109\/10428194.2011.572324","article-title":"High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma","volume":"52","author":"Lane","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.03.018_bib30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bbmt.2012.02.006","article-title":"Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation","volume":"18","author":"Zhang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/bmt.2009.133","article-title":"Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen","volume":"45","author":"Beri","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A\u00a0comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib33","unstructured":"Pasquini MC, Wang Z, Horowitz MM, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clinical Transplants. 2010:87-105. Los Angeles, CA: The Terasaki Foundation Laboratory; 2011."},{"key":"10.1016\/j.bbmt.2016.03.018_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.03.018_bib36","first-page":"813","article-title":"Safety of PK-guided IV Bu Cy VP-16 preparative regimen prior to autologous hematopoietic stem cell\u00a0transplantation for lymphoma: findings from a multi-center phase II study in North America","volume":"120","author":"Costa","year":"2012","journal-title":"ASH Annual Meet Abstr"},{"key":"10.1016\/j.bbmt.2016.03.018_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule","volume":"13","author":"Madden","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/bbmt.2002.v8.abbmt080619","article-title":"A\u00a0limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan","volume":"8","author":"Vaughan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib39","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2007.06.005","article-title":"Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation","volume":"13","author":"Ryu","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2011.06.013","article-title":"Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients","volume":"18","author":"Yeh","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","article-title":"Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation","volume":"20","author":"Slattery","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2016.03.018_bib42","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.03.018_bib43","series-title":"Survival analysis: state of the art","first-page":"237","article-title":"Cox-type regression analysis for large numbers of small groups of correlated failure time observations","author":"Lee","year":"1992"},{"key":"10.1016\/j.bbmt.2016.03.018_bib44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2016.03.018_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/bmt.2009.133","article-title":"Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen","volume":"45","author":"Beri","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbmt.2005.12.028","volume":"12","author":"Kletzel","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2011.07.015","article-title":"Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing","volume":"18","author":"Kangarloo","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00280-014-2660-0","article-title":"Dosing algorithm revisit for busulfan following IV infusion","volume":"75","author":"Wang","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2016.03.018_bib49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bbmt.2010.07.016","article-title":"Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies","volume":"17","author":"Kebriaei","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","article-title":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma","volume":"34","author":"Wang","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.03.018_bib51","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bbmt.2015.05.016","article-title":"Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116001671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116001671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:54:52Z","timestamp":1761058492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116001671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1083879116001671"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.018","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}